AstraZeneca PLC (LON:AZN) Receives Average Rating of “Moderate Buy” from Analysts

AstraZeneca PLC (LON:AZN) has earned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is £101.62 ($135.93).

Several analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a £110 ($147.14) price objective on shares of AstraZeneca in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a report on Monday, September 16th. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a report on Thursday, July 25th. Berenberg Bank reissued a “buy” rating and set a £150 ($200.64) price objective on shares of AstraZeneca in a research note on Monday, September 2nd. Finally, Jefferies Financial Group lifted their target price on shares of AstraZeneca from GBX 71 ($0.95) to GBX 74 ($0.99) and gave the stock a “hold” rating in a research note on Tuesday, July 2nd.

Insider Buying and Selling at AstraZeneca

In other news, insider Michel Demare bought 2,000 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The shares were acquired at an average cost of GBX 118 ($1.58) per share, with a total value of £2,360 ($3,156.77). 0.04% of the stock is owned by company insiders.

AstraZeneca Price Performance

AZN stock opened at £118.58 ($158.61) on Friday. The stock’s 50 day moving average price is £124.92 and its 200 day moving average price is £120.20. The firm has a market cap of £183.80 billion, a P/E ratio of 3,831.17, a PEG ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 84.97, a quick ratio of 0.59 and a current ratio of 0.89. AstraZeneca has a 1 year low of GBX 9,461 ($126.55) and a 1 year high of £133.88 ($179.08).

AstraZeneca Cuts Dividend

The business also recently declared a dividend, which was paid on Monday, September 9th. Shareholders of record on Thursday, August 8th were paid a dividend of GBX 77.60 ($1.04) per share. This represents a yield of 0.64%. The ex-dividend date of this dividend was Thursday, August 8th. AstraZeneca’s dividend payout ratio is currently 7,597.40%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.